A Phase 3 interventional study of Ravulizumab in Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals, Inc.. Active, not recruiting at 11 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2023, is one of 9 in phase 3, reaches primary completion later than 1 of the 10 other live ones, and was the 10th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Germany, Italy and 1 more country
Ages 18+
AstraZeneca · Sites in Russia
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in Italy
Ages 18+
AstraZeneca · Sites in Poland
Ages 18+
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2023.
This study's enrollment of 12 is below the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 20 across the 13 interventional studies, 263 across the 6 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
4 of the studies in Myasthenia Gravis by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT07596784Phase 3Alexion Pharmaceuticals, Inc.Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | 2027-08-24 |
| NCT06967480Alexion Pharmaceuticals, Inc.Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis | 2027-06-30 |
| NCT07221838Alexion Pharmaceuticals, Inc.A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | 2027-08-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical Conditions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a weight-based loading dose of ravulizumab IV on Day 1, followed by weight-based maintenance dose of ravulizumab on Day 15 and once every 8 weeks (q8w) thereafter for participants weighing ≥ 20 kg, or once every 4 weeks (q4w) for participants weighing \< 20 kg, for a total of 122 weeks of treatment.
Drug: Ravulizumab
Ravulizumab will be administered by intravenous (IV) infusion.
Serum Concentration of Ravulizumab
Time frame: Day 1 predose through Week 18 predose
Serum Free C5 Concentration
Time frame: Day 1 predose through Week 18 predose
Change From Baseline in The Quantitative Myasthenia Gravis (QMG) Total Score at Up to Week 18
Time frame: Baseline, Up to Week 18
Change From Baseline in Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score at Up to Week 18
Time frame: Baseline, Up to Week 18
Change From Baseline in Myasthenia Gravis Composite (MGC) Score at Up to Week 18
Time frame: Baseline, Up to Week 18
Change in Status from Week 10 in Myasthenia Gravis Foundation of America Postintervention Status (MGFA-PIS) as Assessed by the Investigator or Neurologist at Up to Week 18
Time frame: Week 10, Up to Week 18
Change from Baseline in Neurology Quality of Life (Neuro QoL) Pediatric Fatigue Score at Up to Week 18
Participants ≥8 years of age will be evaluated.
Time frame: Baseline, Up to Week 18
Change from Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Parent Proxy - Fatigue Score at Up to Week 18
Participants \<8 years of age will be evaluated.
Time frame: Baseline, Up to Week 18
Number of Participants With ≥5-point Reduction Compared to Baseline in the QMG Total Score Over Time Through Week 18
Time frame: Baseline through Week 18
Number of Participants With ≥3 point Reduction Compared to Baseline in the MG-ADL Total Score Over Time Through Week 18
Time frame: Baseline through Week 18
Number of Participants That Improve or Remain Stable in QMG Total Score at Week 18 Compared to Baseline
Stable is defined as a ±5-point change from Baseline.
Time frame: Baseline through Week 18
Number of Participants That Improve or Remain Stable in MG ADL Total Score at Week 18 Compared to Baseline
Stable is defined as a ±3-point change from baseline.
Time frame: Baseline through Week 18
Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
Time frame: Baseline up to Week 126 (8 weeks after last dose of study drug)
Number of Participants With Anti-Drug Antibody (ADA) at Week 18
Time frame: Baseline through Week 18
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Jul 2026, 36 months after the start.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 36 months is above that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Alexion Pharmaceuticals, Inc. →